Recent Quotes (30 days)

You have no recent quotes
chg | %

Theratechnologies Inc  

(Public, TSE:TH)   Watch this stock  
Find more results for TH
-0.020 (-3.39%)
Delayed:   1:26PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.57 - 0.58
52 week 0.19 - 0.65
Open 0.58
Vol / Avg. 3,086.00/79,817.00
Mkt cap 34.78M
P/E     -
Div/yield     -
EPS -0.12
Shares 61.01M
Beta 0.64
Inst. own     -

Key stats and ratios

Q2 (May '14) 2013
Net profit margin 42.08% -53.69%
Operating margin -136.23% -59.35%
EBITD margin - -102.71%
Return on average assets 13.83% -13.26%
Return on average equity 26.17% -19.69%
Employees 18 -
CDP Score - -


2310 Alfred-Nobel Blvd.
+1-514-3367800 (Phone)
+1-514-3367242 (Fax)

Website links


Theratechnologies Inc. is a biopharmaceutical company that specializes in therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. The Company�s product, EGRIFTA (tesamorelin for injection), is approved by the United States Food and Drug Administration indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA is commercialized in the United States by EMD Serono, Inc. pursuant to a collaboration and licensing agreement.

Officers and directors

Dawn Svoronos Chairman of the Board
Age: 60
Luc Tanguay President, Chief Executive Officer, Director
Age: 54
Marie-Noel Colussi Vice President - Finance
Age: 44
Jocelyn Lafond Vice President - Legal Affairs, Corporate Secretary
Age: 45
Christian Marsolais Ph.D. Vice President - Scientific Affairs and Alliances
Age: 50
Pierre Perazzelli Vice President - Pharmaceutical Development
Age: 61
Krishna Peri Ph.D. Vice President - Research
Paul Pommier MBA Director
Age: 70
Gilles Cloutier Ph.D. Independent Director
Age: 68
Dawn Graham Independent Director
Age: 60